News room

Lyon, France - April 2008
genOway (ALTERNEXT-NYSE:ALGEN ; ISIN: FR0004053510), the biotechnology company dedicated to the development of genetically modified animal models reports the signing of a master services agreement with the Japanese pharmaceutical leader Eisai Co., Ltd.

Under the terms of this new collaborative agreement, genOway will provide its client with both customized genetically modified mouse lines tailored to the researchers’ needs and ready-for-use animal models selectable from its catalogue of standardized products. This contract can be increased to include additional models. genOway has been chosen thanks to the company’s expertise and capacity to create highly sophisticated animal models by means of an industrialized production process.

"Due to our continued effort to improve our industrial platform and our aggressive in-licensing strategy in the fields of molecular, cellular biology and embryology, genOway is able to offer more and more sophisticated animal models to the big pharma companies. All these genetically modified models target a better predictive understanding of the action mechanisms during the clinical trials of their molecules", added Kader Thiam, VP Transgenic Technologies at genOway.

To date, genOway makes its expertise available to over 50 major biopharmaceutical groups and 175 academic institutions, either through customized development of genetically modified research animal models or through its emerging activity of sale of proprietary models.

Alexandre Fraichard, CEO of genOway, stated: "In 2006, we signed our first agreement in Japan with ONO Pharmaceuticals. Since our business development team has made a great job on this local market. Today, genOway is working with 4 major nippon pharma companies and has become the leading supplier of research tools in the US, in Europe and in Asia."

Lyon, France - March 2008,
genOway, the biotechnology company dedicated to the development of genetically modifed animal models reports the signing of a master service contract with Boehringer Ingelheim Pharmaceuticals Inc. This agreement is a master service agreement under which genOway will provide its client with customized mouse and rat lines tailored to the researchers' needs. The agreement is a 5-year agreement.

Gilles de Poncins, CFO of genOway stated: "genOway now collaborates with seven of the major worldwide laboratories. It's a privilege and an honor for us to collaborate with these strategic partners".

"2008 will be an exciting year in which genOway expects to emphasize and demonstrate its leadership. The business-development efforts we spread since few months are gainful. In addition to an intensification of our existing activities in Europe and north–America, we hope to announce some exciting news on the Asian market in the near future", added Kader Thiam, VP Transgenic Technologies of genOway.